This is part 4 of an interview. Watch part 1, part 2, and part 3.

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side ...

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting tumor-agnostic high TMB and/or MMR-D eligibility. Increasing TMB did not associate ...

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, training, and follow-up for high-risk patients.

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves ...

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance. This is part 3 of an interview. Watch part 1 and part 2.

In an interview with Targeted OncologyTM, Ranjit Goudar, MD, of Virginia Oncology Associates, discusses the ongoing barriers to genetic testing and hereditary cancer risk assessment, emphasizing that ...

A Big Ten Cancer Research Consortium project is testing counter-marketing, plain-language messages tailored for social media to increase alcohol–breast cancer risk awareness. AI-built social posts aim ...